Amplia Therapeutics Ltd
ATX
Company Profile
Business description
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
Contact
90 William Street
Level 5
MelbourneVIC3000
AUST: +61 391231140
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
SpaceX is scaling AI infrastructure on earth, data centers in space might be next
Our view on the first results as a publicly traded company.
stocks
A look into newly listed Glencore’s valuation
A new ASX heavyweight with coal, copper and trading exposure.
stocks
Meta is up 9% this year. Is it still a buy ahead of earnings?
We’ll be watching Muse agent adoption, revenue growth, and more.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,956.60 | 12.40 | 0.14% |
| CAC 40 | 7,916.78 | 78.29 | 1.00% |
| DAX 40 | 25,680.75 | 376.33 | 1.49% |
| Dow JONES (US) | 52,464.14 | 31.74 | -0.06% |
| FTSE 100 | 10,768.47 | 35.47 | 0.33% |
| HKSE | 23,651.87 | 215.87 | -0.90% |
| NASDAQ | 26,616.18 | 191.36 | 0.72% |
| Nikkei 225 | 64,621.24 | 545.82 | 0.85% |
| NZX 50 Index | 13,761.29 | 129.60 | 0.95% |
| S&P 500 | 7,727.86 | 15.29 | 0.20% |
| S&P/ASX 200 | 8,831.30 | 14.40 | 0.16% |
| SSE Composite Index | 3,713.03 | 22.34 | -0.60% |